

Suzhou Kintor enters into agreement with Predicine

09 July 2018 | News

Predicine will develop biomarkers for Kintor's oncology drugs.



China based Suzhou Kintor Pharma has announced a global partnership with Predicine, a US-China diagnostics company, using Predicine's GeneRADAR, a ctRNA + ctDNA liquid biopsy.

Predicine will develop biomarkers for Kintor's oncology drugs. Over the past two years, Kintor and Predicine have formed multiple collaborations to support China-US Phase I-III clinical trials of Kintor's lead candidate, proxalutamide, as a treatment for prostate and breast cancer.

According to Predicine, GeneRADAR is the first liquid biopsy to test both circulating RNA and DNA. Terms of the agreement were not disclosed.

Kintor's oncology pipeline is focused on prostate cancer, breast cancer, and liver cancer.